Skip to content

SELLAS Reports Positive Results For Galinpepimut-S In Blood Cancer Study

SELLAS CEO Angelos Stergiou described the results as a validation of the company’s WT1-targeted immunotherapy technology.

SELLAS Cancer Vaccine Reduces Death Risk by 41% in Phase 3 Trial. Pic via(@washingtonpost)

SELLAS Life Sciences Group announced that its Phase 3 REGAL trial of experimental cancer vaccine galinpepimut-S (GPS) met its primary endpoint, demonstrating a 41% reduction in the risk of death among patients with acute myeloid leukemia (AML).

The study involved 126 patients who achieved a second remission but were ineligible for an allogeneic stem cell transplant.

💡
Patients receiving GPS recorded a median overall survival of 24 months, compared with 14.7 months among those given the investigator’s choice of best available treatment.

SELLAS CEO Angelos Stergiou described the results as a validation of the company’s WT1-targeted immunotherapy technology.

The company plans to meet with the U.S. Food and Drug Administration to discuss an accelerated filing strategy and is preparing for a Biologics License Application submission in the first half of 2027.

Related Tweet:

Also Read:

NIH Chief Seeks Investigation Into Fauci And Collins' Role In COVID-19 Study
He gave the journal 30 days to provide an investigation plan and timetable, suggesting the study could require correction or retraction.

Comments

Latest